BACKGROUND: Ovarian metastases from colorectal cancer (OM-CRC) often are unresponsive to chemotherapy and are associated with poor survival. To the authors' knowledge, the clinicopathologic and genomic predictors of OM-CRC are poorly characterized and optimal clinical management remains unclear. METHODS: Women with a histopathological diagnosis of OM-CRC who were treated at Memorial Sloan Kettering Cancer Center from 1999 to 2015 were identified. Next-generation somatic mutation profiling (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) was performed on 38 OM-CRC cases, including 21 matched tumor pairs/trios. Regression models were used to analyze variables associated with progression-free survival and overall survival (OS). RESULTS: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), SMAD family member 4 (SMAD4), and neurotrophic receptor tyrosine kinase 1 (NTRK1) mutations were more frequent in cases of OM-CRC than in instances of CRC occurring without OM. SMAD4 and lysine methyltransferase 2D (KMT2D) mutations were associated with reduced OS. Matched multisite tumor sequencing did not identify OM-specific genomic alterations. Of the 195 patients who underwent oophorectomy for OM-CRC (median age, 49 years with a progression-free survival of 9.4 months and an OS of 23 months from oophorectomy), 76% had extraovarian metastasis (EOM). In multivariable analysis, residual disease after surgery (R2 resection) was associated with worse survival. Patients with EOM were less likely to achieve R0/R1 surgical resection status (complete macroscopic resection without clinical/radiological evidence of disease) (48% vs 94%). However, if R0/R1 resection status was achieved, both patients with (35.9 months vs 12 months) and without (43.2 months vs 14.5 months) EOM were found to have better OS. Among 114 patients with R0/R1 resection status, 23 (20%) had no disease recurrence, including 10 patients (9%) with > 3 years of follow-up. CONCLUSIONS: Loss-of-function alterations in SMAD4 are frequent and predictive of worse survival in patients with OM-CRC. Similar to oligometastatic CRC to the lung or liver, surgical resection of OM-CRC is associated with a better outcome only if all macroscopic metastatic disease is resected.
INTRODUCTION
Ovarian metastases (OM), which occur in 5% to 10% of all women with metastatic colorectal cancer (CRC), disproportionately affect younger women, and have been associated with a median survival of only 19 to 27 months after detection. 1, 2 In addition, they may cause significant morbidity from pain and abdominal distension 3 and, based on small case series, are believed to be disproportionately unresponsive to chemotherapy, growing to large dimensions while other sites of metastasis respond. 4, 5 Given the limited benefit from chemotherapy, surgical oophorectomy has been practiced as a therapeutic strategy, with small retrospective studies demonstrating better survival in patients who have undergone complete surgical cytoreduction. [6] [7] [8] [9] However, to the best of our knowledge, there are little data and no guidelines to date to inform risk stratification and the selection of patients who may benefit from surgical oophorectomy.
The characterization of OM from CRC (OM-CRC) has been limited by small sample sizes and the inability to radiologically distinguish OM from primary ovarian tumors. 10, 11 Moreover, to our knowledge, few studies have examined the molecular biology of OM. 12, 13 In one study of copy number alterations in CRC metastases, approximately 8.3% of OM were found to harbor coamplification of 6q21 and MYC (8q24.21) that was not identified in the primary tumor. 13 Whether OM-CRC may harbor actionable genomic alterations that may drive a unique chemoresistant biology is not known.
To define clinicopathological and genomic predictors of the incidence and outcomes of OM, we performed a comprehensive, large, single-institution, clinical, pathological, and genetic retrospective study of all patients with confirmed OM-CRC who were treated at Memorial Sloan Kettering Cancer Center (MSKCC) between 1999 and 2015. To rigorously eliminate the ambiguity inherent in purely radiological diagnoses, we focused exclusively on patients who had undergone ovarian metastasectomy and had a histopathological diagnosis of parenchymal OM-CRC.
MATERIALS AND METHODS

Patient Selection
The current study was approved by the Institutional Review Board at MSKCC. Using an electronic database search, we identified all patients treated at MSKCC between January 1, 1999 and January 1, 2015 with International Classification of Diseases, Ninth Revision codes for both CRC (codes 153 and 154) and metastatic cancer to the ovaries (code 198.6). A total of 505 patients were identified, and all charts were reviewed manually. Patients without a histopathological diagnosis of OM-CRC, those with appendiceal or other noncolorectal adenocarcinoma, or those with only superficial serosal involvement of the ovary were excluded.
Baseline characteristics were collected using electronic medical records and included the site of the primary tumor and other metastases at the time of surgical resection of OM; OM laterality; chronology of OM and extraovarian metastasis (EOM); and the histopathological features of the primary tumor, including TNM stage, differentiation, and the presence of lymphovascular invasion, perineural invasion, and tumor-infiltrating lymphocytes. KRAS exon 2 mutation status was identified either from Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) testing or from a mass spectrometry-based genotyping assay (Sequenom Inc, San Diego, Calif), as previously described.
14 Treatment characteristics were collected including surgery dates, chemotherapy regimens, and radiation administered before and after the diagnosis of OM and after oophorectomy. Surgical reports were reviewed to verify the extent of cytoreduction performed during oophorectomy. Response to therapy and time to disease recurrence/ progression after oophorectomy were determined by Response Evaluation Criteria In Solid Tumors (RECIST) and obtained via chart review of radiology reports.
Sample Collection and Sequencing
Tumors from 38 patients with OM-CRC who had either undergone tumor sequencing for clinical decision making or who had provided informed consent for tissue use were profiled genetically, including 21 matched pairs or trios of primary tumor, OM, and EOM from the same patient. Slides from all tissue blocks stained with hematoxylin and eosin were reviewed by a board-certified pathologist (E.V.) before selecting tumor and normal tissue for DNA extraction and sequencing. Samples were macrodissected with the goal of exceeding 60% tumor content. As a comparison control cohort, we used an institutional database of 426 patients with CRC who had undergone single-site tumor sequencing and who were verified by manual chart review to not have OM.
Tumor and germline DNA were sequenced using the MSK-IMPACT, a custom next-generation sequencing assay consisting of an initial panel of 341 cancerassociated genes, with eventual expansion to 410 cancerassociated genes. Sequence read alignment, processing, single-nucleotide variant, and copy number detection were performed as previously described. 15 Mutation and copy number comparison across CRC metastases to multiple organ sites was performed using cBioPortal for Cancer Genomics tools. 16, 17 
Statistical Analysis
For clinical parameters, the primary objective was to identify baseline clinical, genetic, or treatment characteristics that correlated with overall survival (OS) and progressionfree survival (PFS) in all patients who underwent oophorectomy. Secondary objectives were to analyze the correlation between specific genetic alterations and the incidence of OM or OS or PFS after oophorectomy. Kaplan-Meier survival analysis was performed using the R statistical programming language using the survival package (R Foundation for Statistical Computing, Vienna, Austria). The log-rank test was used to determine differences in survival between groups. Variables found to be significant (P .05) by univariate analysis were entered into a multivariate Cox proportional hazards regression model. The association between specific genetic alterations and the incidence of OM was evaluated using the chi-square test.
RESULTS
Baseline and Treatment Characteristics
A total of 195 patients who had undergone oophorectomy and had a pathological diagnosis of parenchymal OM-CRC were included in the current study. The median age of the patients was 49 years at the time of CRC diagnosis and 50 years (range, 17-86 years) at the time of diagnosis of OM. OM were present at the time of the initial CRC diagnosis in 44% of patients, and were bilateral at the time of presentation in 45% of patients. Of the 107 patients who initially presented with unilateral OM, 14 patients (13%) eventually developed metastases in the unresected second ovary. The ovary was the sole metastatic site in 24% of patients, whereas the remaining patients had EOM diagnosed before or simultaneously with OM. The liver (49%) and peritoneum (43%) were the most common sites of EOM. The majority of patients (63%) received chemotherapy before undergoing oophorectomy, with 81% of these patients experiencing discordant growth of OM in comparison with EOM. Discordant growth was defined as either increased tumor size only in the ovaries of at least 20% on 3-dimensional measurement or new OM diagnosed during or after chemotherapy in the absence of other metastases.
Univariate and Multivariate Analysis
Using Kaplan-Meier analysis, we found a median PFS of 9.4 months and a median OS of 23.0 months after oophorectomy ( Fig. 1 ). Univariate analysis was performed to identify baseline and treatment characteristics associated with PFS and OS ( Table 1) . Factors found to correlate with significantly increased PFS and OS were unilateral OM, the absence of lung or liver metastases, the ovary as the first site of metastasis, immediate oophorectomy after a diagnosis of OM, no chemotherapy before OM diagnosis, and the absence of any clinical or radiological metastatic disease in the ovaries or elsewhere (R0/R1 resection status) after metastasectomy ( Fig. 2A) .
Variables with a univariable P value .05 were entered into a Cox logistic regression model using the 191 patients with complete data sets. On multivariable analysis, R0/R1 resection status after surgery was found to be significantly associated with better PFS and OS ( Fig. 2A) ( Table 2) . Liver metastases were associated with worse PFS but not OS, whereas bilateral OM were associated with worse OS but not PFS. We repeated the multivariable analysis including potentially confounding clinical variables in addition to statistically significant variables, and found consistent conclusions (see Supporting Information Table 1 ).
R0/R1 Surgical Resection Is Associated With Increased PFS and OS
Patients with R0/R1 surgical resection status with no macroscopic metastatic disease after surgery were found to have increased PFS and OS ( Fig. 2A) . We used the presence of EOM before or at the time of ovarian metastasectomy to discern the benefit from oophorectomy. An increasing number of sites of EOM was found to be associated with worse PFS (P<.0001) and OS (P<.0001) ( Fig. 2A) .
Because patients with EOM might be expected to be more likely to have unresectable disease, we analyzed whether the survival difference associated with oophorectomy (and additional metastasectomy as needed) was restricted to those patients who did not have EOM. As expected, R0/R1 resection status was achieved more frequently in patients who did not have EOM (P<.0001) ( Fig. 2B) . Nearly all patients with OM only (94% of 149 patients) were able to achieve R0/R1 resection status, whereas only 48% of 46 patients with EOM had no residual disease after surgery. However, when R0/R1 surgical resection was achieved, both patients with (median survival, 36 months vs 12 months) and without (median survival, 43 months vs 15 months) EOM had significantly better OS in comparison with patients with R2 resection status (Fig. 2B ). There was no difference noted with regard to OS or PFS among patients with or without EOM (P 5 .07 for PFS and P 5 .36 for OS) when R0/R1 resection status was achieved. Fifteen patients who achieved R0/ R1 resection status (5 patients with and 10 patients without prior EOM) were followed for at least 3 years after undergoing oophorectomy, 10 of whom (67%; 4 patients with and 6 patients without prior EOM) remained free of disease for the duration of follow-up (median follow-up, 86 months [range, 53-199 months]). Furthermore, we analyzed differences between the group of 10 patients with long-term disease-free survival and the subgroup of patients with OS <6 months (22 patients). In the group of longterm survivors, there was a significant association noted with absence of EOM (P 5 .001), fewer sites of EOM (P 5 .0006), and R0/R1 resection status (P 5 .0002).
Sequencing of Matched Multisite Tumors From the Same Patients Identified No Recurrent Ovary-Specific Genomic Aberrations
Because the OM studied displayed discordant growth and selective chemoresistance in comparison with primary tumors and EOM, we analyzed whether ovaryspecific genomic aberrations were responsible for driving such growth. MSK-IMPACT performed on 21 matched pairs or trios of primary tumors, OM, and other metastases from the same patient revealed no recurrent OM-specific mutations or copy number variations, although nonrecurrent private mutations in 1 sites occasionally were observed (Fig. 3) . Across the 38 cases profiled, the most frequently mutated genes were TP53 (76.3%), APC (68.4%), KRAS (65.8%), SMAD4 (39.4%), and PIK3CA (23.7%). Other genes with mutations or copy number alterations in at least 5% of cases are shown in Figure 3 . To determine whether the presence of specific genetic aberrations was associated with outcome in patients with OM, we applied univariable and multivariable analysis to the 38 patients for whom there were complete mutation data (see Supporting Information (Fig. 4B) . Furthermore, we compared the frequency of specific genetic aberrations among tumors with discordant growth of OM and those that responded concordantly with EOM when treated with chemotherapy. SRY-box 9 (SOX9) was found to be mutated in approximately 50% of the concordant group, but in only 7.8% of the discordant group (P 5 .02)
DISCUSSION
To the best of our knowledge, the current study is the largest study to systematically characterize the clinical and mutational landscape of OM-CRC and the first to characterize genetic aberrations in OM-CRC. Because radiographic studies are inadequate to discriminate between primary ovarian tumors and OM from tumors of the colorectum or other sites, we focused on tumors that had been surgically removed and had histopathologically confirmed OM-CRC. With this methodology, we found that, in contrast to prior reports, only 43% of patients with parenchymal OM had concurrent peritoneal carcinomatosis, and that peritoneal involvement was not associated with worse OS in this selected patient cohort. 6, 18 In concordance with prior smaller studies, the results of the current study demonstrated that OM occurred in younger women, frequently displayed disproportionate growth during chemotherapy, and were associated with poor prognosis in comparison with national trends for metastatic CRC. 19 The results of the current study demonstrate that macroscopic surgical cytoreduction of OM and other metastases is strongly associated with better PFS and OS, which is consistent with prior studies. [6] [7] [8] [9] The current study data support that, when achieved, cytoreduction has equivalent outcomes in patients with or without extraovarian disease. Because the majority of cases of CRC recurrence occur within 3 years of surgery, we used 3-year recurrence-free survival as a surrogate for cure. Of 15 patients who underwent R0/R1 surgical resection who were subsequently followed for at least 3 years, 10 patients had no further recurrence of CRC. These data suggest that optimal surgical debulking of OM and other metastases may potentially be curative or, at a minimum, lead to substantial disease-free survival in a subset of patients. Furthermore, the presence of SMAD4 and KMT2D alterations was associated with reduced OS, although this requires prospective validation in a larger patient cohort.
In the current study, we identified increased frequencies of alterations in KRAS, SMAD4, and NTRK1 in patients with OM-CRC, suggesting that the oncogenic properties conferred by aberrant ERK, transforming growth factor b, and neurotrophin signaling may contribute to both metastasis to the ovaries and aggressive tumor biology elsewhere. The conservation of genomic alterations among primary tumors and metastases from different sites from the same patient is consistent with the "predestination hypothesis," which posits that primary tumors contain the full genomic program required for the eventual phenotype of a tumor, 20 as well as with our prior data, 21 which demonstrated a high concordance of mutations in matched primary and metastatic CRC tumors from sites other than the ovary. Because the current study used targeted exome sequencing, it remains possible that OM may harbor aberrations in unsequenced regions of the genome that may drive their aggressive behavior and chemoresistance. Furthermore, the ovary may represent a "sanctuary site" that presents a favorable microenvironment for tumor growth. 5 Although the current study was based on a small cohort, we intriguingly identified differential mutation burden in SOX9 among tumors with concordant versus discordant responses, suggesting that tumor genetics potentially may drive differential microenvironmental interaction and treatment response. However, it is clinically significant that although 81% of OM in the current study demonstrated discordant growth on chemotherapy, such growth did not correlate with reduced PFS (P 5 .25) or OS (P 5 .36) after metastasectomy.
Limitations of the current study include that it was a retrospective analysis from a single institution with the inclusion of patients with only histopathologically confirmed OM-CRC who were selected for surgery. Although histopathological confirmation of OM-CRC was essential for eliminating the ambiguity in radiologically distinguishing OM from primary ovarian tumors or peritoneal metastases, which can manifest as serosal seeding of the ovarian surface, this did result in the exclusion of some women with unresectable OM-CRC. We initially also attempted to stratify patients who had been treated with oophorectomy for curative versus palliative intent; however, this was not feasible due to incomplete documentation and discordant radiographical and intraoperative assessments of disease extent, necessitating change in surgical strategy. As such, we used the presence of EOM before or at the time of ovarian metastasectomy to discern the benefit from oophorectomy, demonstrating that as long as all disease could be resected, ovarian metastasectomy was beneficial.
The results of the current study suggest that patients with OM-CRC compromise a clinical subgroup characterized by younger women with poor overall clinical prognosis and discordant ovarian response to chemotherapy. It is interesting to note that we identified that frequent alterations in SMAD4 and KMT2D in patients with OM-CRC are associated with poor prognosis. Building on these data, future work may enable the genetic risk stratification of women with OM-CRC, with potential clinical usefulness in identifying candidates for surgery or other therapy. The current study has provided evidence for the use of ovarian metastasectomy in patients with unilateral or bilateral OM, and in patients for whom no evidence of disease after surgery is thought to be achievable. Oophorectomy may be curative for some patients who undergo optimal surgical cytoreduction, including surgical resection of all EOM. However, in patients with unresectable EOM, oophorectomy should be reserved for symptom palliation. The input of a multispecialty disease management team is paramount in optimizing the appropriate selection of patients for surgical resection. 
